Approach to the Patient Treated with Steroidogenesis Inhibitors

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2021 Mar 6

PMID 33675650

Citations 17

Authors

Frederic Castinetti

Lynnette K Nieman

Martin Reincke

John Newell-Price

Affiliations

Soon will be listed here.

Abstract

Steroidogenesis inhibitors can be given to control the hypercortisolism of Cushing's syndrome in various situations: when surgery has been unsuccessful or not possible; in metastatic adrenocorticotropin hormone (ACTH) or cortisol-secreting tumors; when waiting for the maximal efficacy of radiation techniques; for rapid treatment of severe hypercortisolism in patients with occult ACTH-producing tumors; or as a presurgical treatment in patients with severe comorbidities. Whilst biochemical "control" can be achieved in more than 50% of cases, daily management of such drugs can be challenging. Indeed, with a "dose-titration" or a "block and replace" approach, defining eucortisolism is usually difficult, requiring the measurement of several biological markers. Moreover, each drug has its own side effects, which must be monitored closely. The aim of this "approach to the patient" is to shed light on the management of hypercortisolism with 4 steroidogenesis inhibitors (ketoconazole, levoketoconazole, metyrapone, osilodrostat) to help endocrinologists dealing with patients with Cushing's syndrome. Various points will be discussed, such as initial dose of treatment, dose schedule, monitoring of efficacy, and side effects of monotherapy. The combination of steroidogenesis inhibitors will also be discussed.

Citing Articles

Hormone circuit explains why most HPA drugs fail for mood disorders and predicts the few that work.

Milo T, Nir Halber S, Raz M, Danan D, Mayo A, Alon U Mol Syst Biol. 2025; 21(3):254-273.

PMID: 39849227 PMC: 11876312. DOI: 10.1038/s44320-024-00083-0.

Cushing syndrome.

Nieman L, Castinetti F, Newell-Price J, Valassi E, Drouin J, Takahashi Y Nat Rev Dis Primers. 2025; 11(1):4.

PMID: 39848955 DOI: 10.1038/s41572-024-00588-w.

Successful Treatment of Severe Ectopic ACTH-Dependent Cushing Syndrome Complicated by Hypocalcemia With Osilodrostat.

Lee K, Mendes Pessoa C, Huang W JCEM Case Rep. 2025; 3(2):luae255.

PMID: 39839756 PMC: 11744044. DOI: 10.1210/jcemcr/luae255.

Medical Treatment of Cushing's Syndrome.

Guignat L, Bertherat J Endocrinol Metab (Seoul). 2025; 40(1):26-38.

PMID: 39801039 PMC: 11898324. DOI: 10.3803/EnM.2024.501.

Cushing's Syndrome in Pregnancy Secondary to Adrenocortical Adenoma: A Case Series and Review.

Wang Y, An Y, Hou X, Xu Y, Li Z, Liu X Endocrinol Diabetes Metab. 2024; 7(2):e00474.

PMID: 38475883 PMC: 10933386. DOI: 10.1002/edm2.474.

References

Geer E, Salvatori R, Elenkova A, Fleseriu M, Pivonello R, Witek P . Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome. Pituitary. 2020; 24(1):104-115. PMC: 7864823. DOI: 10.1007/s11102-020-01103-6. View

Rousseau E, Joubert M, Trzepla G, Parienti J, Freret T, Vanthygem M . Usefulness of Time-Point Serum Cortisol and ACTH Measurements for the Adjustment of Glucocorticoid Replacement in Adrenal Insufficiency. PLoS One. 2015; 10(8):e0135975. PMC: 4552782. DOI: 10.1371/journal.pone.0135975. View

Petersenn S, Newell-Price J, Findling J, Gu F, Maldonado M, Sen K . High variability in baseline urinary free cortisol values in patients with Cushing's disease. Clin Endocrinol (Oxf). 2013; 80(2):261-9. PMC: 4231220. DOI: 10.1111/cen.12259. View

Mah P, Jenkins R, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V . Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2004; 61(3):367-75. DOI: 10.1111/j.1365-2265.2004.02106.x. View

Corcuff J, Young J, Masquefa-Giraud P, Chanson P, Baudin E, Tabarin A . Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. Eur J Endocrinol. 2015; 172(4):473-81. DOI: 10.1530/EJE-14-0913. View

Schwartz S, Rendell M, Ahmann A, Thomas A, Arauz-Pacheco C, Welles B . Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus. Clin Ther. 2008; 30(6):1081-8. DOI: 10.1016/j.clinthera.2008.05.021. View

Brue T, Amodru V, Castinetti F . MANAGEMENT OF ENDOCRINE DISEASE: Management of Cushing's syndrome during pregnancy: solved and unsolved questions. Eur J Endocrinol. 2018; 178(6):R259-R266. DOI: 10.1530/EJE-17-1058. View

Newell-Price J, Nieman L, Reincke M, Tabarin A . ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing's syndrome. Eur J Endocrinol. 2020; 183(1):G1-G7. PMC: 7938010. DOI: 10.1530/EJE-20-0352. View

Pivonello R, de Leo M, Cozzolino A, Colao A . The Treatment of Cushing's Disease. Endocr Rev. 2015; 36(4):385-486. PMC: 4523083. DOI: 10.1210/er.2013-1048. View

10.

Baudry C, Coste J, Bou Khalil R, Silvera S, Guignat L, Guibourdenche J . Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol. 2012; 167(4):473-81. DOI: 10.1530/EJE-12-0358. View

11.

Constantinescu S, Driessens N, Lefebvre A, Furnica R, Corvilain B, Maiter D . Etomidate infusion at low doses is an effective and safe treatment for severe Cushing's syndrome outside intensive care. Eur J Endocrinol. 2020; 183(2):161-167. DOI: 10.1530/EJE-20-0380. View

12.

Newell-Price J, Pivonello R, Tabarin A, Fleseriu M, Witek P, Gadelha M . Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease. Eur J Endocrinol. 2019; 182(2):207-217. PMC: 7003692. DOI: 10.1530/EJE-19-0695. View

13.

Feelders R, Newell-Price J, Pivonello R, Nieman L, Hofland L, Lacroix A . Advances in the medical treatment of Cushing's syndrome. Lancet Diabetes Endocrinol. 2018; 7(4):300-312. DOI: 10.1016/S2213-8587(18)30155-4. View

14.

Tritos N . Adrenally Directed Medical Therapies for Cushing Syndrome. J Clin Endocrinol Metab. 2020; 106(1):16-25. DOI: 10.1210/clinem/dgaa778. View

15.

Kamenicky P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier J . Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab. 2011; 96(9):2796-804. DOI: 10.1210/jc.2011-0536. View

16.

Azzola A, Eastabrook G, Matsui D, Berberich A, Tirona R, Gray D . Adrenal Cushing Syndrome Diagnosed During Pregnancy: Successful Medical Management With Metyrapone. J Endocr Soc. 2020; 5(1):bvaa167. PMC: 7712789. DOI: 10.1210/jendso/bvaa167. View

17.

Dilmaghanian S, Gerber J, Filler S, Sanchez A, Gal J . Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates. Chirality. 2004; 16(2):79-85. DOI: 10.1002/chir.10294. View

18.

Debono M, Harrison R, Chadarevian R, Gueroult C, Abitbol J, Newell-Price J . Resetting the Abnormal Circadian Cortisol Rhythm in Adrenal Incidentaloma Patients With Mild Autonomous Cortisol Secretion. J Clin Endocrinol Metab. 2017; 102(9):3461-3469. PMC: 5587065. DOI: 10.1210/jc.2017-00823. View

19.

Nieman L, Biller B, Findling J, Murad M, Newell-Price J, Savage M . Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(8):2807-31. PMC: 4525003. DOI: 10.1210/jc.2015-1818. View

20.

Fleseriu M, Castinetti F . Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies. Pituitary. 2016; 19(6):643-653. PMC: 5080363. DOI: 10.1007/s11102-016-0742-1. View